stockrow
Monday 9 November 2026
Export NGEN’s income statement to Excel — free account
NervGen Pharma Corp.
NGEN- EPS
- +192.2%
- Free cash flow
- −48.1%
Quarter to June 2026, against a year earlier
1.33
0.01
+0.76%
Follow NGEN
Alert me
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+3 more TTM periods Free account |
— | (1,037.51%) | (1,203.00%) | (94.85%) | |
| — | (205.27%) | (230.19%) | (40.66%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
0.00% | (805.79%) | (802.86%) | (46.88%) | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.30) | (0.19) | (0.21) | (0.20) | |
Free Cash Flow |
(21.80) | (13.96) | (17.06) | (18.39) | |
| Other line items | |||||
Cash ROIC |
(355.20%) | (69.70%) | (105.93%) | (19.05%) | |
Accounts Receivable Turnover |
— | 0.00 | 0.00 | 0.00 | |
Accounts Payable Turnover |
— | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
— | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
— | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
— | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
— | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.00 | 0.44 | 0.57 | 1.17 | |
Depreciation/Fixed assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.30) | (0.19) | (0.21) | (0.20) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates · fundamentals updated 2 Nov 2026